This protocol covers patients with AL amyloidosis who have relapsed or have refractory disease, and in whom the disease retains sensitivity to bortezomib. The presence of bortezomib sensitivity is the central factor that defines this clinical situation and informs the choice of regimen.
Bortezomib (V)-sensitive disease in the relapsed or refractory setting. Confirming this sensitivity is essential before applying this protocol, as it directly drives regimen selection.
The recommended strategy involves a daratumumab-based or bortezomib-based combination regimen. Multiple options within this class may be considered, with the choice depending on individual clinical factors. The complete regimen details, including selection criteria and sequencing, are available in the full protocol.
DOI: 10.1200/OP.22.00396